Overview

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Camptothecin
Capecitabine
Irinotecan
Taxane